James Toll

Director, Finance & Operations

A serial entrepreneur with extensive experience in the securities industry. Founded an investment advisory company, developed a family of alternative indexing products, and provided option education services. Previously Director of OTC Trading at Mercury Trading, a member of the Chicago Board Options Exchange, and a member of the CBOE's Product Development Committee. Received a BA in Economics from Trinity University in San Antonio, TX.

The Aortix™ device is currently in the research and development phase and is not available for sale in any country.
Caution: Investigational Device. Limited by Federal Law to Investigational Use.

Links

HomeClinical TrialsOverviewTeamNewsCareersReferencesDisclaimer & Terms of UseContact

LATEST NEWS

March 2023
Press Release
Aortix™ Pump Therapy Leads to Rapid Decongestion and Improved Kidney Function in Hospitalized Patients with Heart Failure and Worsening Renal Function
February 2023
Press Release
Procyrion Announces Successful First-in-Human Cases with Aortix™ Pump to Prevent Acute Kidney Injury in Patients Undergoing Cardiac Surgery
November 2021
Press Release
Procyrion’s Aortix™ Percutaneous Mechanical Circulatory Support Device to be Showcased at TCT 2021 Annual Meeting

ABOUT US

Procyrion is a team of experienced life science entrepreneurs, engineers, cardiologists, and heart failure specialists.

Our dedicated team is working to address the unmet clinical needs of heart failure patients through the development of a safe and innovative percutaneous mechanical circulatory support (pMCS) device.

Copyright © 2021 Procyrion, Inc.
Disclaimer & Terms of Use
Aortix™ is for investigational use only and is not for sale in the United States.